Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of telitacicept for ocular myasthenia gravis
ChiCTR2600135289Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in myasthenia gravis (MG), sponsored by Huashan Hospital. Primary endpoint: Myasthenia Gravis Injury Index (MGII) at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2600135289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135289.